echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > International Chemical > Sumitomo Chemical to exit caprolactam business

    Sumitomo Chemical to exit caprolactam business

    • Last Update: 2022-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sinochem News recently, Sumitomo Chemical announced that the company will decommission its 85,000-ton/year caprolactam production facility in Niihama, Ehime Prefecture in October 2022


    S&P Global Commodities Insights' Chemical Economics Handbook shows that Japan, once a major caprolactam producer in Asia, has grown its capacity at 6 per year since 2015 due to weak global demand, a shift in capacity to other Asian producers and a loss of overall competitiveness.


    The company added that while caprolactam production will be discontinued, operations at its Niihama plant will continue and respond to market demand




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.